Conjunctivitis, Bacterial
8
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Treatment Research
12 treatments under study, led by Gatifloxacin
Research Leaders
6 sponsors active, led by Laboratorios Sophia S.A de C.V.
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
12.5%
1 terminated out of 8 trials
83.3%
-3.3% vs benchmark
38%
3 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (8)
Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults
Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.
Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists
Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects
Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.
Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
Systemic Pharmacokinetics of BOL-303224-A
Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
Research Network
Common Treatments
- Gatifloxacin1
- Azithromycin 15 Loteprednol 05 Separately1
- Dunk1
- Levofloxacin 05 Eye Drops Solution Oftaquix1
- Pazufloxacin1
Active Sponsors
- Laboratorios Sophia S.A de C.V.3
- Adapt Produtos Oftalmológicos Ltda.1
- Laboratoires Thea1
- NTC srl1
- Bausch & Lomb Incorporated1
Top Investigators
Laboratorios Sophia S.A de C.V.
Federal University of São Paulo / Hospital São Paulo
Ospedale San Raffaele IRCCS S.r.l.
Independent Clinical Research Center
CHU d'Angers, France
Related Conditions
- Conjunctivitis1
- Ocular Inflammation1
- Keratitis1
- Keratitis Bacterial1
- Infection Associated Blepharitis1